Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Abdom Radiol (NY). 2020 Nov;45(11):3743-3754. doi: 10.1007/s00261-020-02562-y.
To evaluate the diagnostic performance of LR-M criteria for differentiating hepatocellular carcinoma, intrahepatic mass-forming cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma and to compare the imaging features of each type.
In this retrospective study, 110 patients were surgically diagnosed with cholangiocarcinoma (n = 67) and combined hepatocellular-cholangiocarcinoma (n = 43) at a single tertiary hospital between 2013 and 2018. Among them, those with risk factors were enrolled (16 cholangiocarcinomas and 33 combined hepatocellular-cholangiocarcinomas). Forty-nine other patients with size-matched hepatocellular carcinoma were selected as a control group. Two independent readers evaluated the imaging findings of the preoperative MRIs based on LI-RADS version 2018 and assigned an LI-RADS category. The diagnostic performance of the LR-M criteria for diagnosing cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma was evaluated, and the imaging features were compared. The imaging findings of the tumors in patients without risk factors (51 cholangiocarcinomas and 10 combined hepatocellular-cholangiocarcinomas) were evaluated for subgroup analysis.
In the non-hepatocellular carcinoma group, 33 patients were categorized into LR-M and 14 patients into LR-5 (67.3% and 28.6%, respectively), while 5 patients with hepatocellular carcinoma were categorized into LR-M and 38 patients into LR-5 (10.2% and 77.6%, respectively). Sensitivity and specificity of the LR-M criteria were 67.3% and 89.8%, respectively. When more than two LR-M features were present, cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma were suggested with a specificity of 95.9%.
The diagnostic performance of the LR-M criteria is acceptable with moderate sensitivity and high specificity for both cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma. Imaging findings of primary hepatic carcinomas should be understood as a spectrum.
评估 LR-M 标准在鉴别肝细胞癌、肝内肿块型胆管细胞癌和混合型肝癌中的诊断性能,并比较每种类型的影像学特征。
本回顾性研究纳入了 2013 年至 2018 年期间在一家三级医院因胆管癌(n=67)和混合型肝癌(n=43)接受手术治疗的 110 名患者。其中,有危险因素的患者被纳入研究(16 例胆管癌和 33 例混合型肝癌)。另外选择了 49 名大小匹配的肝细胞癌患者作为对照组。两位独立的读者基于 LI-RADS 2018 版评估了术前 MRI 的影像学表现,并分配了 LI-RADS 类别。评估了 LR-M 标准对胆管癌或混合型肝癌的诊断性能,并比较了影像学特征。对无危险因素的患者(51 例胆管癌和 10 例混合型肝癌)的肿瘤影像学表现进行了亚组分析。
在非肝细胞癌组中,33 例患者被归类为 LR-M,14 例患者被归类为 LR-5(分别为 67.3%和 28.6%),而 5 例肝细胞癌患者被归类为 LR-M,38 例患者被归类为 LR-5(分别为 10.2%和 77.6%)。LR-M 标准的敏感性和特异性分别为 67.3%和 89.8%。当存在两个以上的 LR-M 特征时,提示为胆管癌或混合型肝癌,特异性为 95.9%。
LR-M 标准的诊断性能对于胆管癌和混合型肝癌具有中等敏感性和较高特异性。原发性肝癌的影像学表现应被理解为一个连续谱。